Stem definition | Drug id | CAS RN |
---|---|---|
aromatase inhibitors, imidazole-triazole derivatives | 210 | 120511-73-1 |
Dose | Unit | Route |
---|---|---|
1 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.50 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 10 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.06 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 80 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 27, 1995 | FDA | ASTRAZENECA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Metastases to bone | 1105.59 | 11.70 | 468 | 50535 | 20551 | 63417468 |
Malignant neoplasm progression | 829.12 | 11.70 | 616 | 50387 | 81505 | 63356514 |
Metastases to liver | 615.04 | 11.70 | 324 | 50679 | 23315 | 63414704 |
Metastases to lung | 483.94 | 11.70 | 226 | 50777 | 12524 | 63425495 |
Osteonecrosis | 352.83 | 11.70 | 229 | 50774 | 24301 | 63413718 |
Hot flush | 348.11 | 11.70 | 305 | 50698 | 50854 | 63387165 |
Breast cancer recurrent | 290.63 | 11.70 | 115 | 50888 | 4226 | 63433793 |
Breast cancer metastatic | 282.37 | 11.70 | 154 | 50849 | 11864 | 63426155 |
Disease progression | 275.22 | 11.70 | 411 | 50592 | 122347 | 63315672 |
Bone pain | 257.63 | 11.70 | 266 | 50737 | 54375 | 63383644 |
Metastases to lymph nodes | 241.41 | 11.70 | 122 | 50881 | 8036 | 63429983 |
Neoplasm progression | 241.38 | 11.70 | 214 | 50789 | 36214 | 63401805 |
Drug ineffective | 238.79 | 11.70 | 295 | 50708 | 1044470 | 62393549 |
Breast cancer | 230.72 | 11.70 | 237 | 50766 | 48146 | 63389873 |
Neutropenia | 218.59 | 11.70 | 453 | 50550 | 174552 | 63263467 |
Osteonecrosis of jaw | 202.74 | 11.70 | 191 | 50812 | 34932 | 63403087 |
Tumour marker increased | 198.54 | 11.70 | 91 | 50912 | 4824 | 63433195 |
Ejection fraction decreased | 186.65 | 11.70 | 150 | 50853 | 22182 | 63415837 |
White blood cell count decreased | 184.19 | 11.70 | 369 | 50634 | 138735 | 63299284 |
Contraindicated product administered | 156.02 | 11.70 | 4 | 50999 | 217644 | 63220375 |
Maternal exposure during pregnancy | 154.25 | 11.70 | 5 | 50998 | 220057 | 63217962 |
Metastasis | 151.66 | 11.70 | 77 | 50926 | 5120 | 63432899 |
Tooth extraction | 143.08 | 11.70 | 94 | 50909 | 10170 | 63427849 |
Metastases to spine | 133.89 | 11.70 | 61 | 50942 | 3188 | 63434831 |
Infusion related reaction | 131.77 | 11.70 | 20 | 50983 | 245501 | 63192518 |
Pseudocirrhosis | 130.77 | 11.70 | 40 | 50963 | 667 | 63437352 |
Systemic lupus erythematosus | 129.87 | 11.70 | 10 | 50993 | 208908 | 63229111 |
Therapeutic product effect decreased | 120.78 | 11.70 | 9 | 50994 | 193178 | 63244841 |
Synovitis | 116.02 | 11.70 | 9 | 50994 | 186909 | 63251110 |
Arthralgia | 114.23 | 11.70 | 815 | 50188 | 568895 | 62869124 |
Neuropathy peripheral | 104.71 | 11.70 | 261 | 50742 | 113406 | 63324613 |
Bone lesion | 97.25 | 11.70 | 60 | 50943 | 5821 | 63432198 |
Treatment failure | 96.46 | 11.70 | 21 | 50982 | 199022 | 63238997 |
Carbohydrate antigen 15-3 increased | 95.66 | 11.70 | 38 | 50965 | 1410 | 63436609 |
Metastases to pleura | 92.33 | 11.70 | 38 | 50965 | 1547 | 63436472 |
Rheumatoid arthritis | 91.16 | 11.70 | 45 | 50958 | 253774 | 63184245 |
Joint swelling | 90.69 | 11.70 | 78 | 50925 | 327588 | 63110431 |
Osteopenia | 89.03 | 11.70 | 94 | 50909 | 19691 | 63418328 |
Trigger finger | 83.30 | 11.70 | 49 | 50954 | 4359 | 63433660 |
Completed suicide | 82.54 | 11.70 | 10 | 50993 | 145663 | 63292356 |
Glossodynia | 82.46 | 11.70 | 21 | 50982 | 178855 | 63259164 |
Osteolysis | 82.16 | 11.70 | 42 | 50961 | 2832 | 63435187 |
Bone disorder | 81.51 | 11.70 | 93 | 50910 | 21233 | 63416786 |
Pericarditis | 79.80 | 11.70 | 7 | 50996 | 131572 | 63306447 |
Fatigue | 75.56 | 11.70 | 1063 | 49940 | 886965 | 62551054 |
Pain in jaw | 70.63 | 11.70 | 126 | 50877 | 43370 | 63394649 |
Vitreoretinal traction syndrome | 68.80 | 11.70 | 13 | 50990 | 17 | 63438002 |
Ascites | 68.74 | 11.70 | 120 | 50883 | 40608 | 63397411 |
Myalgia | 67.97 | 11.70 | 265 | 50738 | 146264 | 63291755 |
Lymphoedema | 66.32 | 11.70 | 63 | 50940 | 11629 | 63426390 |
Drug hypersensitivity | 66.01 | 11.70 | 92 | 50911 | 310595 | 63127424 |
Tonsillar disorder | 64.99 | 11.70 | 27 | 50976 | 1126 | 63436893 |
Lacrimation increased | 64.13 | 11.70 | 81 | 50922 | 20550 | 63417469 |
Metastases to central nervous system | 63.88 | 11.70 | 65 | 50938 | 13040 | 63424979 |
PIK3CA-activated mutation | 63.77 | 11.70 | 26 | 50977 | 1033 | 63436986 |
Metastases to pelvis | 63.73 | 11.70 | 21 | 50982 | 450 | 63437569 |
Nasal disorder | 62.59 | 11.70 | 35 | 50968 | 2829 | 63435190 |
Wound | 61.59 | 11.70 | 27 | 50976 | 163236 | 63274783 |
Acute myeloid leukaemia | 60.88 | 11.70 | 72 | 50931 | 17075 | 63420944 |
Organising pneumonia | 57.39 | 11.70 | 43 | 50960 | 5733 | 63432286 |
Off label use | 55.94 | 11.70 | 316 | 50687 | 674146 | 62763873 |
Retinal toxicity | 55.90 | 11.70 | 25 | 50978 | 1250 | 63436769 |
Sequestrectomy | 55.69 | 11.70 | 22 | 50981 | 804 | 63437215 |
Arthropathy | 55.60 | 11.70 | 64 | 50939 | 234728 | 63203291 |
Malignant pleural effusion | 54.65 | 11.70 | 31 | 50972 | 2575 | 63435444 |
Vulvovaginal dryness | 54.17 | 11.70 | 32 | 50971 | 2869 | 63435150 |
Cystoid macular oedema | 53.87 | 11.70 | 26 | 50977 | 1549 | 63436470 |
Debridement | 53.78 | 11.70 | 24 | 50979 | 1194 | 63436825 |
Toxicity to various agents | 52.71 | 11.70 | 73 | 50930 | 247177 | 63190842 |
Abdominal discomfort | 52.62 | 11.70 | 112 | 50891 | 320773 | 63117246 |
Hypersensitivity | 51.55 | 11.70 | 98 | 50905 | 292587 | 63145432 |
Metastases to chest wall | 51.51 | 11.70 | 19 | 50984 | 574 | 63437445 |
Osteomyelitis | 51.02 | 11.70 | 82 | 50921 | 25938 | 63412081 |
Psoriatic arthropathy | 50.10 | 11.70 | 7 | 50996 | 91513 | 63346506 |
Intentional product use issue | 50.08 | 11.70 | 20 | 50983 | 127872 | 63310147 |
Leukopenia | 48.98 | 11.70 | 155 | 50848 | 77135 | 63360884 |
Breast cancer female | 48.25 | 11.70 | 57 | 50946 | 13502 | 63424517 |
Endometrial hyperplasia | 47.56 | 11.70 | 20 | 50983 | 860 | 63437159 |
Metastases to the mediastinum | 47.48 | 11.70 | 17 | 50986 | 471 | 63437548 |
Metastatic neoplasm | 47.25 | 11.70 | 34 | 50969 | 4261 | 63433758 |
Bone sequestrum | 46.42 | 11.70 | 23 | 50980 | 1451 | 63436568 |
Swelling | 46.08 | 11.70 | 95 | 50908 | 275283 | 63162736 |
Irritable bowel syndrome | 45.83 | 11.70 | 6 | 50997 | 82406 | 63355613 |
Second primary malignancy | 45.39 | 11.70 | 43 | 50960 | 7910 | 63430109 |
Metastases to abdominal wall | 45.22 | 11.70 | 12 | 50991 | 116 | 63437903 |
Fasciitis | 44.56 | 11.70 | 17 | 50986 | 565 | 63437454 |
Invasive ductal breast carcinoma | 44.32 | 11.70 | 40 | 50963 | 6918 | 63431101 |
Interstitial lung disease | 43.75 | 11.70 | 129 | 50874 | 61779 | 63376240 |
Drug abuse | 43.57 | 11.70 | 4 | 50999 | 72514 | 63365505 |
Oestradiol increased | 43.53 | 11.70 | 11 | 50992 | 86 | 63437933 |
Sinusitis | 43.40 | 11.70 | 72 | 50931 | 226581 | 63211438 |
Polyneuropathy | 43.33 | 11.70 | 56 | 50947 | 14533 | 63423486 |
Peritoneal disorder | 43.30 | 11.70 | 16 | 50987 | 486 | 63437533 |
Folliculitis | 41.92 | 11.70 | 4 | 50999 | 70313 | 63367706 |
Pleural effusion | 41.92 | 11.70 | 167 | 50836 | 93043 | 63344976 |
Product use issue | 40.44 | 11.70 | 72 | 50931 | 220448 | 63217571 |
Excessive eye blinking | 40.39 | 11.70 | 20 | 50983 | 1260 | 63436759 |
Hypotension | 39.96 | 11.70 | 101 | 50902 | 272503 | 63165516 |
Pathological fracture | 39.79 | 11.70 | 42 | 50961 | 8792 | 63429227 |
Discomfort | 39.19 | 11.70 | 46 | 50957 | 167328 | 63270691 |
Thrombocytopenia | 37.82 | 11.70 | 229 | 50774 | 150928 | 63287091 |
Dry skin | 37.80 | 11.70 | 116 | 50887 | 56771 | 63381248 |
Nail disorder | 37.16 | 11.70 | 49 | 50954 | 12966 | 63425053 |
Hair growth abnormal | 36.04 | 11.70 | 25 | 50978 | 2956 | 63435063 |
Red blood cell count decreased | 35.99 | 11.70 | 92 | 50911 | 40553 | 63397466 |
Muscle injury | 35.76 | 11.70 | 5 | 50998 | 65340 | 63372679 |
Hepatic enzyme increased | 34.50 | 11.70 | 69 | 50934 | 202259 | 63235760 |
Hypertensive angiopathy | 34.20 | 11.70 | 9 | 50994 | 84 | 63437935 |
Drug intolerance | 34.15 | 11.70 | 130 | 50873 | 308531 | 63129488 |
Musculoskeletal chest pain | 34.12 | 11.70 | 61 | 50942 | 21022 | 63416997 |
Breast pain | 33.00 | 11.70 | 38 | 50965 | 8760 | 63429259 |
Gene mutation | 32.76 | 11.70 | 19 | 50984 | 1646 | 63436373 |
Palmar-plantar erythrodysaesthesia syndrome | 32.74 | 11.70 | 63 | 50940 | 22952 | 63415067 |
Sialoadenitis | 32.69 | 11.70 | 19 | 50984 | 1653 | 63436366 |
Pleural neoplasm | 32.65 | 11.70 | 12 | 50991 | 359 | 63437660 |
Oestrogen receptor assay positive | 32.31 | 11.70 | 13 | 50990 | 499 | 63437520 |
Tumour marker abnormal | 32.15 | 11.70 | 12 | 50991 | 375 | 63437644 |
Metastases to soft tissue | 32.03 | 11.70 | 10 | 50993 | 179 | 63437840 |
Uterine polyp | 31.59 | 11.70 | 20 | 50983 | 2030 | 63435989 |
Dental care | 31.38 | 11.70 | 16 | 50987 | 1073 | 63436946 |
Gingival swelling | 31.34 | 11.70 | 27 | 50976 | 4391 | 63433628 |
Blister | 31.12 | 11.70 | 35 | 50968 | 129779 | 63308240 |
Injection site pain | 31.11 | 11.70 | 35 | 50968 | 129765 | 63308254 |
Metastases to spinal cord | 31.01 | 11.70 | 9 | 50994 | 124 | 63437895 |
Injection site erythema | 30.96 | 11.70 | 14 | 50989 | 83160 | 63354859 |
Carpal tunnel syndrome | 30.87 | 11.70 | 58 | 50945 | 20759 | 63417260 |
Injection site reaction | 30.83 | 11.70 | 5 | 50998 | 58519 | 63379500 |
Tendonitis | 30.78 | 11.70 | 56 | 50947 | 19559 | 63418460 |
Soft tissue neoplasm | 30.76 | 11.70 | 8 | 50995 | 71 | 63437948 |
Pancreatic neoplasm | 30.72 | 11.70 | 14 | 50989 | 732 | 63437287 |
Portal hypertension | 30.52 | 11.70 | 25 | 50978 | 3794 | 63434225 |
Metastases to skin | 30.15 | 11.70 | 18 | 50985 | 1645 | 63436374 |
Intentional overdose | 30.01 | 11.70 | 11 | 50992 | 74141 | 63363878 |
Mouth swelling | 29.70 | 11.70 | 27 | 50976 | 4713 | 63433306 |
Loss of personal independence in daily activities | 29.59 | 11.70 | 21 | 50982 | 97269 | 63340750 |
Decreased appetite | 29.54 | 11.70 | 320 | 50683 | 250732 | 63187287 |
Product substitution issue | 29.45 | 11.70 | 49 | 50954 | 15947 | 63422072 |
Pain | 29.36 | 11.70 | 419 | 50584 | 740209 | 62697810 |
Dysgeusia | 28.96 | 11.70 | 93 | 50910 | 46617 | 63391402 |
Blood alkaline phosphatase increased | 28.90 | 11.70 | 88 | 50915 | 42879 | 63395140 |
Chronic inflammatory demyelinating polyradiculoneuropathy | 28.47 | 11.70 | 12 | 50991 | 519 | 63437500 |
Hyperparathyroidism primary | 28.19 | 11.70 | 11 | 50992 | 389 | 63437630 |
Tooth loss | 28.08 | 11.70 | 31 | 50972 | 6825 | 63431194 |
Acute phase reaction | 28.07 | 11.70 | 10 | 50993 | 273 | 63437746 |
Oestradiol abnormal | 27.90 | 11.70 | 7 | 50996 | 53 | 63437966 |
Ischaemic stroke | 27.84 | 11.70 | 51 | 50952 | 17906 | 63420113 |
Periodontal disease | 27.72 | 11.70 | 17 | 50986 | 1631 | 63436388 |
Radiation skin injury | 27.59 | 11.70 | 14 | 50989 | 929 | 63437090 |
Hepatic lesion | 27.37 | 11.70 | 26 | 50977 | 4799 | 63433220 |
Leiomyosarcoma recurrent | 27.18 | 11.70 | 5 | 50998 | 5 | 63438014 |
Vitreous detachment | 26.88 | 11.70 | 18 | 50985 | 2009 | 63436010 |
Condition aggravated | 26.85 | 11.70 | 201 | 50802 | 402016 | 63036003 |
Joint neoplasm | 26.83 | 11.70 | 7 | 50996 | 63 | 63437956 |
C-reactive protein abnormal | 26.50 | 11.70 | 3 | 51000 | 46093 | 63391926 |
Tumour marker decreased | 26.35 | 11.70 | 7 | 50996 | 68 | 63437951 |
Resorption bone increased | 26.30 | 11.70 | 15 | 50988 | 1259 | 63436760 |
Hair texture abnormal | 26.26 | 11.70 | 24 | 50979 | 4219 | 63433800 |
Anaemia | 26.22 | 11.70 | 355 | 50648 | 293075 | 63144944 |
Retinal detachment | 26.21 | 11.70 | 28 | 50975 | 5941 | 63432078 |
Neutrophil count decreased | 26.11 | 11.70 | 102 | 50901 | 56304 | 63381715 |
Gingivitis | 26.04 | 11.70 | 33 | 50970 | 8396 | 63429623 |
Mucosal inflammation | 26.04 | 11.70 | 90 | 50913 | 46838 | 63391181 |
Cardiotoxicity | 26.02 | 11.70 | 33 | 50970 | 8405 | 63429614 |
Oral pain | 25.90 | 11.70 | 65 | 50938 | 28329 | 63409690 |
Metastases to thorax | 25.57 | 11.70 | 9 | 50994 | 237 | 63437782 |
Progesterone receptor assay positive | 25.46 | 11.70 | 10 | 50993 | 360 | 63437659 |
Exposed bone in jaw | 25.18 | 11.70 | 20 | 50983 | 2905 | 63435114 |
Nausea | 25.16 | 11.70 | 879 | 50124 | 853592 | 62584427 |
Metastases to retroperitoneum | 24.98 | 11.70 | 8 | 50995 | 156 | 63437863 |
Hormone receptor positive breast cancer | 24.92 | 11.70 | 11 | 50992 | 533 | 63437486 |
Haemorrhoids | 24.87 | 11.70 | 55 | 50948 | 22095 | 63415924 |
Recurrent cancer | 24.81 | 11.70 | 17 | 50986 | 1970 | 63436049 |
Ovarian cancer | 24.44 | 11.70 | 27 | 50976 | 5949 | 63432070 |
Metastases to peritoneum | 24.35 | 11.70 | 21 | 50982 | 3421 | 63434598 |
Product use in unapproved indication | 24.22 | 11.70 | 69 | 50934 | 179011 | 63259008 |
Full blood count decreased | 24.18 | 11.70 | 60 | 50943 | 25964 | 63412055 |
Fibrous histiocytoma | 24.12 | 11.70 | 11 | 50992 | 576 | 63437443 |
Fracture | 23.56 | 11.70 | 50 | 50953 | 19534 | 63418485 |
Nail avulsion | 23.54 | 11.70 | 8 | 50995 | 189 | 63437830 |
Injection site pruritus | 23.44 | 11.70 | 4 | 50999 | 45112 | 63392907 |
Nail infection | 23.34 | 11.70 | 18 | 50985 | 2505 | 63435514 |
Bone density decreased | 23.29 | 11.70 | 42 | 50961 | 14570 | 63423449 |
Tooth disorder | 23.15 | 11.70 | 62 | 50941 | 28095 | 63409924 |
Recall phenomenon | 23.05 | 11.70 | 11 | 50992 | 639 | 63437380 |
Hiccups | 23.04 | 11.70 | 17 | 50986 | 2214 | 63435805 |
Superinfection | 22.82 | 11.70 | 18 | 50985 | 2589 | 63435430 |
Therapeutic product effect incomplete | 22.75 | 11.70 | 41 | 50962 | 125015 | 63313004 |
Catheter site bruise | 22.72 | 11.70 | 10 | 50993 | 481 | 63437538 |
Jaundice | 22.65 | 11.70 | 63 | 50940 | 29188 | 63408831 |
Neoplasm recurrence | 22.63 | 11.70 | 18 | 50985 | 2620 | 63435399 |
Cholestasis | 22.40 | 11.70 | 63 | 50940 | 29371 | 63408648 |
Fibromyalgia | 22.37 | 11.70 | 19 | 50984 | 80401 | 63357618 |
Osteosclerosis | 22.14 | 11.70 | 21 | 50982 | 3867 | 63434152 |
Hair colour changes | 21.96 | 11.70 | 19 | 50984 | 3108 | 63434911 |
Bone debridement | 21.84 | 11.70 | 8 | 50995 | 237 | 63437782 |
Urticaria | 21.61 | 11.70 | 65 | 50938 | 165737 | 63272282 |
Tumour flare | 21.58 | 11.70 | 9 | 50994 | 379 | 63437640 |
Pneumonia | 21.53 | 11.70 | 249 | 50754 | 456518 | 62981501 |
Acquired gene mutation | 21.44 | 11.70 | 12 | 50991 | 971 | 63437048 |
Transient acantholytic dermatosis | 21.43 | 11.70 | 6 | 50997 | 72 | 63437947 |
Polymyositis | 21.42 | 11.70 | 15 | 50988 | 1801 | 63436218 |
Full blood count abnormal | 21.37 | 11.70 | 65 | 50938 | 31652 | 63406367 |
Peripheral swelling | 21.19 | 11.70 | 126 | 50877 | 265816 | 63172203 |
Antisynthetase syndrome | 21.14 | 11.70 | 6 | 50997 | 76 | 63437943 |
Autoimmune pancreatitis | 20.85 | 11.70 | 8 | 50995 | 270 | 63437749 |
Human epidermal growth factor receptor negative | 20.79 | 11.70 | 5 | 50998 | 31 | 63437988 |
Diarrhoea | 20.54 | 11.70 | 734 | 50269 | 714632 | 62723387 |
Type 2 diabetes mellitus | 20.47 | 11.70 | 13 | 50990 | 63855 | 63374164 |
Jaw operation | 20.23 | 11.70 | 11 | 50992 | 841 | 63437178 |
Cutaneous vasculitis | 20.17 | 11.70 | 23 | 50980 | 5246 | 63432773 |
Cardiomyopathy | 20.13 | 11.70 | 44 | 50959 | 17540 | 63420479 |
Metastases to bone marrow | 20.07 | 11.70 | 9 | 50994 | 453 | 63437566 |
Papilloedema | 19.95 | 11.70 | 20 | 50983 | 3940 | 63434079 |
Vertebral column mass | 19.83 | 11.70 | 7 | 50996 | 186 | 63437833 |
Atypical femur fracture | 19.80 | 11.70 | 23 | 50980 | 5349 | 63432670 |
Blood copper increased | 19.80 | 11.70 | 4 | 50999 | 9 | 63438010 |
Joint stiffness | 19.61 | 11.70 | 76 | 50927 | 41793 | 63396226 |
Asthenia | 19.60 | 11.70 | 424 | 50579 | 383180 | 63054839 |
Wheezing | 19.58 | 11.70 | 29 | 50974 | 95566 | 63342453 |
Henoch-Schonlein purpura | 19.57 | 11.70 | 12 | 50991 | 1151 | 63436868 |
Uterine leiomyoma | 19.43 | 11.70 | 30 | 50973 | 9168 | 63428851 |
Vascular purpura | 19.30 | 11.70 | 13 | 50990 | 1465 | 63436554 |
Psoriasis | 19.19 | 11.70 | 25 | 50978 | 86932 | 63351087 |
Overdose | 18.96 | 11.70 | 40 | 50963 | 115038 | 63322981 |
Knee arthroplasty | 18.84 | 11.70 | 10 | 50993 | 54196 | 63383823 |
Bone marrow failure | 18.78 | 11.70 | 59 | 50944 | 29231 | 63408788 |
Spinal pain | 18.73 | 11.70 | 36 | 50967 | 13103 | 63424916 |
Epistaxis | 18.69 | 11.70 | 111 | 50892 | 72614 | 63365405 |
Left ventricular dysfunction | 18.53 | 11.70 | 34 | 50969 | 11954 | 63426065 |
Breast mass | 18.39 | 11.70 | 27 | 50976 | 7895 | 63430124 |
Jaw disorder | 18.23 | 11.70 | 22 | 50981 | 5327 | 63432692 |
Septic shock | 18.22 | 11.70 | 16 | 50987 | 66613 | 63371406 |
Gastrointestinal disorder | 18.16 | 11.70 | 50 | 50953 | 131189 | 63306830 |
Asthma | 18.10 | 11.70 | 48 | 50955 | 127513 | 63310506 |
Neoplasm malignant | 18.10 | 11.70 | 59 | 50944 | 29802 | 63408217 |
Actinomycosis | 18.09 | 11.70 | 11 | 50992 | 1039 | 63436980 |
Bacteriuria | 18.07 | 11.70 | 11 | 50992 | 1042 | 63436977 |
Pyrexia | 17.94 | 11.70 | 268 | 50735 | 470210 | 62967809 |
Carbohydrate antigen 27.29 increased | 17.86 | 11.70 | 5 | 50998 | 60 | 63437959 |
Medication error | 17.66 | 11.70 | 10 | 50993 | 52274 | 63385745 |
Tongue neoplasm malignant stage unspecified | 17.59 | 11.70 | 10 | 50993 | 834 | 63437185 |
Osteitis | 17.36 | 11.70 | 17 | 50986 | 3257 | 63434762 |
Injection site bruising | 17.33 | 11.70 | 6 | 50997 | 41904 | 63396115 |
Carcinoembryonic antigen increased | 17.22 | 11.70 | 13 | 50990 | 1752 | 63436267 |
Atrophic vulvovaginitis | 17.21 | 11.70 | 13 | 50990 | 1755 | 63436264 |
Alopecia | 17.20 | 11.70 | 373 | 50630 | 337163 | 63100856 |
Purulent discharge | 17.10 | 11.70 | 20 | 50983 | 4686 | 63433333 |
Plantar fasciitis | 17.09 | 11.70 | 18 | 50985 | 3757 | 63434262 |
Heart rate increased | 17.05 | 11.70 | 31 | 50972 | 94207 | 63343812 |
Invasive lobular breast carcinoma | 17.05 | 11.70 | 10 | 50993 | 885 | 63437134 |
Osteoporosis | 17.04 | 11.70 | 91 | 50912 | 57247 | 63380772 |
Sedation | 17.03 | 11.70 | 5 | 50998 | 38804 | 63399215 |
Neoplasm | 17 | 11.70 | 25 | 50978 | 7320 | 63430699 |
Intraductal proliferative breast lesion | 16.95 | 11.70 | 16 | 50987 | 2929 | 63435090 |
Autoimmune hepatitis | 16.93 | 11.70 | 27 | 50976 | 8483 | 63429536 |
Blood pressure fluctuation | 16.92 | 11.70 | 8 | 50995 | 46309 | 63391710 |
Multiple sclerosis relapse | 16.77 | 11.70 | 9 | 50994 | 48469 | 63389550 |
Peripheral sensory neuropathy | 16.73 | 11.70 | 25 | 50978 | 7426 | 63430593 |
Acute promyelocytic leukaemia | 16.72 | 11.70 | 10 | 50993 | 917 | 63437102 |
Vaginal discharge | 16.70 | 11.70 | 28 | 50975 | 9170 | 63428849 |
Disease recurrence | 16.65 | 11.70 | 55 | 50948 | 27975 | 63410044 |
Joint range of motion decreased | 16.57 | 11.70 | 3 | 51000 | 32425 | 63405594 |
Toothache | 16.52 | 11.70 | 43 | 50960 | 19156 | 63418863 |
Endometrial hypertrophy | 16.45 | 11.70 | 7 | 50996 | 310 | 63437709 |
Neuralgia | 16.42 | 11.70 | 52 | 50951 | 25874 | 63412145 |
Neuroectodermal neoplasm | 16.31 | 11.70 | 3 | 51000 | 3 | 63438016 |
Bronchitis | 16.26 | 11.70 | 49 | 50954 | 124886 | 63313133 |
Nasopharyngitis | 16.03 | 11.70 | 129 | 50874 | 254128 | 63183891 |
Infection | 16.00 | 11.70 | 113 | 50890 | 229060 | 63208959 |
Breast haemorrhage | 15.97 | 11.70 | 6 | 50997 | 191 | 63437828 |
Metastases to uterus | 15.94 | 11.70 | 5 | 50998 | 91 | 63437928 |
Oroantral fistula | 15.91 | 11.70 | 6 | 50997 | 193 | 63437826 |
Visual acuity reduced | 15.91 | 11.70 | 46 | 50957 | 21780 | 63416239 |
Back pain | 15.81 | 11.70 | 299 | 50704 | 263846 | 63174173 |
Metastases to adrenals | 15.77 | 11.70 | 9 | 50994 | 756 | 63437263 |
Prescribed overdose | 15.74 | 11.70 | 4 | 50999 | 34149 | 63403870 |
Tremor | 15.72 | 11.70 | 54 | 50949 | 132185 | 63305834 |
Atrial enlargement | 15.69 | 11.70 | 7 | 50996 | 348 | 63437671 |
Cardio-respiratory arrest | 15.68 | 11.70 | 15 | 50988 | 59944 | 63378075 |
Musculoskeletal stiffness | 15.48 | 11.70 | 86 | 50917 | 184532 | 63253487 |
Constipation | 15.36 | 11.70 | 260 | 50743 | 224683 | 63213336 |
Gamma-glutamyltransferase increased | 15.31 | 11.70 | 61 | 50942 | 33970 | 63404049 |
HER2 positive breast cancer | 15.30 | 11.70 | 7 | 50996 | 369 | 63437650 |
Paratracheal lymphadenopathy | 15.04 | 11.70 | 4 | 50999 | 39 | 63437980 |
Meningioma | 14.94 | 11.70 | 17 | 50986 | 3868 | 63434151 |
Confusional state | 14.87 | 11.70 | 120 | 50883 | 236260 | 63201759 |
Decreased immune responsiveness | 14.85 | 11.70 | 19 | 50984 | 4882 | 63433137 |
Hyperkalaemia | 14.84 | 11.70 | 13 | 50990 | 54190 | 63383829 |
Abdominal wall cyst | 14.78 | 11.70 | 4 | 50999 | 42 | 63437977 |
Wrong technique in product usage process | 14.72 | 11.70 | 17 | 50986 | 62323 | 63375696 |
Prescribed underdose | 14.64 | 11.70 | 3 | 51000 | 29686 | 63408333 |
Hypoaesthesia teeth | 14.61 | 11.70 | 4 | 50999 | 44 | 63437975 |
Incorrect dose administered | 14.55 | 11.70 | 16 | 50987 | 59952 | 63378067 |
Benign lymph node neoplasm | 14.49 | 11.70 | 3 | 51000 | 8 | 63438011 |
Chronic hepatitis | 14.46 | 11.70 | 9 | 50994 | 887 | 63437132 |
Borrelia infection | 14.33 | 11.70 | 6 | 50997 | 255 | 63437764 |
Therapeutic response decreased | 14.29 | 11.70 | 17 | 50986 | 61508 | 63376511 |
Flushing | 14.21 | 11.70 | 24 | 50979 | 75063 | 63362956 |
Oral surgery | 14.11 | 11.70 | 10 | 50993 | 1224 | 63436795 |
Vitreous adhesions | 14.07 | 11.70 | 4 | 50999 | 51 | 63437968 |
Radiation pneumonitis | 14.01 | 11.70 | 11 | 50992 | 1572 | 63436447 |
Bone marrow infiltration | 13.98 | 11.70 | 8 | 50995 | 676 | 63437343 |
Suicide attempt | 13.97 | 11.70 | 17 | 50986 | 60901 | 63377118 |
Radicular pain | 13.83 | 11.70 | 7 | 50996 | 462 | 63437557 |
Lower respiratory tract infection | 13.80 | 11.70 | 57 | 50946 | 132250 | 63305769 |
Cardiac arrest | 13.76 | 11.70 | 34 | 50969 | 92511 | 63345508 |
Romberg test positive | 13.72 | 11.70 | 5 | 50998 | 146 | 63437873 |
Postoperative wound complication | 13.64 | 11.70 | 9 | 50994 | 980 | 63437039 |
Dyspnoea exertional | 13.59 | 11.70 | 89 | 50914 | 60213 | 63377806 |
Dental caries | 13.52 | 11.70 | 28 | 50975 | 10751 | 63427268 |
Metastases to breast | 13.38 | 11.70 | 6 | 50997 | 302 | 63437717 |
Retroperitoneal fibrosis | 13.36 | 11.70 | 6 | 50997 | 303 | 63437716 |
Gingival erythema | 13.35 | 11.70 | 8 | 50995 | 736 | 63437283 |
Pustule | 13.32 | 11.70 | 11 | 50992 | 1688 | 63436331 |
Metastases to eye | 13.31 | 11.70 | 5 | 50998 | 159 | 63437860 |
Loose tooth | 13.30 | 11.70 | 15 | 50988 | 3379 | 63434640 |
Electrocardiogram QT interval | 13.11 | 11.70 | 5 | 50998 | 166 | 63437853 |
Cardiac failure | 13.07 | 11.70 | 119 | 50884 | 89023 | 63348996 |
Ovarian mass | 13.07 | 11.70 | 8 | 50995 | 765 | 63437254 |
Squamous cell breast carcinoma | 13.02 | 11.70 | 3 | 51000 | 15 | 63438004 |
Dysaesthesia | 13 | 11.70 | 17 | 50986 | 4461 | 63433558 |
Urinary casts present | 12.95 | 11.70 | 4 | 50999 | 69 | 63437950 |
Hypercalcaemia | 12.93 | 11.70 | 51 | 50952 | 28271 | 63409748 |
Phlebitis | 12.92 | 11.70 | 21 | 50982 | 6703 | 63431316 |
Rash | 12.78 | 11.70 | 348 | 50655 | 560523 | 62877496 |
Meibomian gland dysfunction | 12.78 | 11.70 | 5 | 50998 | 178 | 63437841 |
Madarosis | 12.74 | 11.70 | 14 | 50989 | 3067 | 63434952 |
Anaphylactic reaction | 12.63 | 11.70 | 21 | 50982 | 66079 | 63371940 |
Acquired porokeratosis | 12.42 | 11.70 | 3 | 51000 | 19 | 63438000 |
Cutaneous sarcoidosis | 12.37 | 11.70 | 6 | 50997 | 361 | 63437658 |
Diabetic hyperosmolar coma | 12.33 | 11.70 | 6 | 50997 | 364 | 63437655 |
Breast cancer in situ | 12.32 | 11.70 | 10 | 50993 | 1498 | 63436521 |
Chronic hepatic failure | 12.31 | 11.70 | 7 | 50996 | 584 | 63437435 |
Oral disorder | 12.30 | 11.70 | 24 | 50979 | 8830 | 63429189 |
Urinary tract infection staphylococcal | 12.27 | 11.70 | 6 | 50997 | 368 | 63437651 |
Unresponsive to stimuli | 12.11 | 11.70 | 6 | 50997 | 33810 | 63404209 |
Reflux gastritis | 12.10 | 11.70 | 9 | 50994 | 1186 | 63436833 |
Poor peripheral circulation | 12.10 | 11.70 | 15 | 50988 | 3734 | 63434285 |
Hospitalisation | 12.08 | 11.70 | 32 | 50971 | 85049 | 63352970 |
Ageusia | 12.07 | 11.70 | 31 | 50972 | 13697 | 63424322 |
Paraneoplastic syndrome | 11.97 | 11.70 | 7 | 50996 | 616 | 63437403 |
Periodontitis | 11.94 | 11.70 | 14 | 50989 | 3289 | 63434730 |
Pneumonitis | 11.93 | 11.70 | 58 | 50945 | 35164 | 63402855 |
Mood swings | 11.92 | 11.70 | 37 | 50966 | 18211 | 63419808 |
Renal vein thrombosis | 11.86 | 11.70 | 6 | 50997 | 396 | 63437623 |
Dyshidrotic eczema | 11.85 | 11.70 | 7 | 50996 | 627 | 63437392 |
Intentional self-injury | 11.85 | 11.70 | 3 | 51000 | 25684 | 63412335 |
Ovarian neoplasm | 11.85 | 11.70 | 8 | 50995 | 905 | 63437114 |
Granulocyte count decreased | 11.81 | 11.70 | 9 | 50994 | 1231 | 63436788 |
Skin atrophy | 11.79 | 11.70 | 17 | 50986 | 4889 | 63433130 |
Hyperthyroidism | 11.75 | 11.70 | 32 | 50971 | 14641 | 63423378 |
Gingival ulceration | 11.72 | 11.70 | 8 | 50995 | 922 | 63437097 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Growth retardation | 86.52 | 25.60 | 20 | 1839 | 1828 | 34953244 |
Mesenteric vein thrombosis | 78.04 | 25.60 | 16 | 1843 | 833 | 34954239 |
Performance enhancing product use | 68.04 | 25.60 | 10 | 1849 | 67 | 34955005 |
Secondary hypogonadism | 48.00 | 25.60 | 9 | 1850 | 293 | 34954779 |
Haematocrit increased | 44.20 | 25.60 | 12 | 1847 | 2101 | 34952971 |
Metastases to bone | 39.55 | 25.60 | 17 | 1842 | 11953 | 34943119 |
Spondylolisthesis | 39.52 | 25.60 | 9 | 1850 | 768 | 34954304 |
Glucose tolerance decreased | 37.60 | 25.60 | 6 | 1853 | 73 | 34954999 |
Breast cancer recurrent | 36.37 | 25.60 | 5 | 1854 | 19 | 34955053 |
Autoimmune thyroiditis | 35.82 | 25.60 | 9 | 1850 | 1165 | 34953907 |
Blood testosterone increased | 35.10 | 25.60 | 9 | 1850 | 1264 | 34953808 |
Libido decreased | 34.75 | 25.60 | 12 | 1847 | 4684 | 34950388 |
Oestradiol increased | 31.24 | 25.60 | 5 | 1854 | 62 | 34955010 |
Product use issue | 30.69 | 25.60 | 26 | 1833 | 63190 | 34891882 |
Off label use | 30.67 | 25.60 | 68 | 1791 | 419456 | 34535616 |
Portal vein thrombosis | 29.28 | 25.60 | 10 | 1849 | 3778 | 34951294 |
Osteonecrosis of jaw | 27.37 | 25.60 | 15 | 1844 | 17874 | 34937198 |
Intentional product misuse | 26.85 | 25.60 | 21 | 1838 | 45590 | 34909482 |
Androgenetic alopecia | 26.53 | 25.60 | 3 | 1856 | 0 | 34955072 |
Insulin-like growth factor increased | 25.72 | 25.60 | 7 | 1852 | 1236 | 34953836 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Metastases to bone | 740.63 | 11.71 | 324 | 40968 | 24103 | 79678993 |
Malignant neoplasm progression | 421.83 | 11.71 | 431 | 40861 | 135559 | 79567537 |
Metastases to liver | 404.65 | 11.71 | 225 | 41067 | 28089 | 79675007 |
Metastases to lung | 349.29 | 11.71 | 176 | 41116 | 17987 | 79685109 |
Hot flush | 327.01 | 11.71 | 252 | 41040 | 54625 | 79648471 |
Breast cancer recurrent | 273.61 | 11.71 | 89 | 41203 | 2888 | 79700208 |
Breast cancer metastatic | 260.23 | 11.71 | 114 | 41178 | 8488 | 79694608 |
Breast cancer | 236.65 | 11.71 | 171 | 41121 | 33610 | 79669486 |
Osteonecrosis | 216.89 | 11.71 | 157 | 41135 | 30938 | 79672158 |
Bone pain | 216.37 | 11.71 | 200 | 41092 | 55542 | 79647554 |
Arthralgia | 192.62 | 11.71 | 691 | 40601 | 571112 | 79131984 |
Neoplasm progression | 192.04 | 11.71 | 181 | 41111 | 51501 | 79651595 |
Metastases to lymph nodes | 168.95 | 11.71 | 90 | 41202 | 10307 | 79692789 |
Tumour marker increased | 156.99 | 11.71 | 65 | 41227 | 4207 | 79698889 |
Ejection fraction decreased | 153.78 | 11.71 | 134 | 41158 | 34443 | 79668653 |
Osteonecrosis of jaw | 152.25 | 11.71 | 147 | 41145 | 43079 | 79660017 |
White blood cell count decreased | 151.31 | 11.71 | 314 | 40978 | 187974 | 79515122 |
Disease progression | 149.97 | 11.71 | 309 | 40983 | 184053 | 79519043 |
Pseudocirrhosis | 149.68 | 11.71 | 40 | 41252 | 640 | 79702456 |
Fatigue | 142.24 | 11.71 | 893 | 40399 | 928834 | 78774262 |
Drug ineffective | 125.59 | 11.71 | 231 | 41061 | 1080682 | 78622414 |
Tooth extraction | 113.91 | 11.71 | 71 | 41221 | 10924 | 79692172 |
Metastases to spine | 113.82 | 11.71 | 52 | 41240 | 4272 | 79698824 |
Alopecia | 108.83 | 11.71 | 314 | 40978 | 231041 | 79472055 |
Osteopenia | 108.58 | 11.71 | 84 | 41208 | 18280 | 79684816 |
Carbohydrate antigen 15-3 increased | 103.30 | 11.71 | 34 | 41258 | 1145 | 79701951 |
Neutropenia | 99.28 | 11.71 | 351 | 40941 | 287359 | 79415737 |
Completed suicide | 89.49 | 11.71 | 11 | 41281 | 245756 | 79457340 |
Metastasis | 83.03 | 11.71 | 49 | 41243 | 6831 | 79696265 |
Bone lesion | 78.99 | 11.71 | 45 | 41247 | 5874 | 79697222 |
Vitreoretinal traction syndrome | 75.87 | 11.71 | 13 | 41279 | 14 | 79703082 |
Toxicity to various agents | 74.82 | 11.71 | 65 | 41227 | 421475 | 79281621 |
Tonsillar disorder | 74.05 | 11.71 | 27 | 41265 | 1239 | 79701857 |
Trigger finger | 72.51 | 11.71 | 38 | 41254 | 4207 | 79698889 |
Neuropathy peripheral | 71.47 | 11.71 | 197 | 41095 | 141108 | 79561988 |
Infusion related reaction | 67.31 | 11.71 | 18 | 41274 | 230219 | 79472877 |
Lacrimation increased | 65.48 | 11.71 | 69 | 41223 | 22408 | 79680688 |
Lymphoedema | 65.27 | 11.71 | 53 | 41239 | 12360 | 79690736 |
Retinal toxicity | 64.06 | 11.71 | 25 | 41267 | 1386 | 79701710 |
Osteolysis | 62.19 | 11.71 | 35 | 41257 | 4463 | 79698633 |
Therapeutic product effect decreased | 60.46 | 11.71 | 7 | 41285 | 163856 | 79539240 |
Cystoid macular oedema | 59.10 | 11.71 | 26 | 41266 | 1954 | 79701142 |
Metastases to pleura | 58.30 | 11.71 | 24 | 41268 | 1530 | 79701566 |
Synovitis | 56.72 | 11.71 | 6 | 41286 | 150728 | 79552368 |
Endometrial hyperplasia | 54.35 | 11.71 | 18 | 41274 | 618 | 79702478 |
Vulvovaginal dryness | 53.10 | 11.71 | 25 | 41267 | 2199 | 79700897 |
Bone disorder | 52.72 | 11.71 | 57 | 41235 | 19056 | 79684040 |
Maternal exposure during pregnancy | 52.51 | 11.71 | 5 | 41287 | 136533 | 79566563 |
Pain in jaw | 51.97 | 11.71 | 89 | 41203 | 46062 | 79657034 |
Malignant pleural effusion | 51.39 | 11.71 | 28 | 41264 | 3352 | 79699744 |
Nasal disorder | 51.22 | 11.71 | 29 | 41263 | 3740 | 79699356 |
Invasive ductal breast carcinoma | 51.03 | 11.71 | 34 | 41258 | 5858 | 79697238 |
Hypotension | 50.93 | 11.71 | 94 | 41198 | 440223 | 79262873 |
Nausea | 49.36 | 11.71 | 731 | 40561 | 956465 | 78746631 |
Treatment failure | 46.76 | 11.71 | 15 | 41277 | 170471 | 79532625 |
Fasciitis | 45.93 | 11.71 | 17 | 41275 | 814 | 79702282 |
Metastases to central nervous system | 45.46 | 11.71 | 49 | 41243 | 16326 | 79686770 |
Myalgia | 45.02 | 11.71 | 203 | 41089 | 185438 | 79517658 |
Nail disorder | 44.93 | 11.71 | 42 | 41250 | 11810 | 79691286 |
Peritoneal disorder | 44.20 | 11.71 | 16 | 41276 | 719 | 79702377 |
Vaginal discharge | 43.81 | 11.71 | 34 | 41258 | 7429 | 79695667 |
Oestradiol increased | 42.01 | 11.71 | 10 | 41282 | 97 | 79702999 |
Intentional overdose | 40.42 | 11.71 | 4 | 41288 | 105956 | 79597140 |
Systemic lupus erythematosus | 40.42 | 11.71 | 7 | 41285 | 121142 | 79581954 |
Sialoadenitis | 40.25 | 11.71 | 20 | 41272 | 1981 | 79701115 |
Drug abuse | 40.09 | 11.71 | 17 | 41275 | 162674 | 79540422 |
Oestrogen receptor assay positive | 39.19 | 11.71 | 12 | 41280 | 318 | 79702778 |
Uterine polyp | 38.42 | 11.71 | 18 | 41274 | 1566 | 79701530 |
Acute myeloid leukaemia | 38.03 | 11.71 | 62 | 41230 | 30823 | 79672273 |
Pleural neoplasm | 37.91 | 11.71 | 12 | 41280 | 356 | 79702740 |
Hypertensive angiopathy | 36.79 | 11.71 | 9 | 41283 | 99 | 79702997 |
Breast pain | 36.67 | 11.71 | 32 | 41260 | 8233 | 79694863 |
Pneumonia | 36.54 | 11.71 | 197 | 41095 | 660049 | 79043047 |
Metastases to breast | 36.42 | 11.71 | 11 | 41281 | 278 | 79702818 |
Musculoskeletal chest pain | 35.05 | 11.71 | 53 | 41239 | 24711 | 79678385 |
Metastases to pelvis | 34.61 | 11.71 | 13 | 41279 | 649 | 79702447 |
Mouth swelling | 34.29 | 11.71 | 27 | 41265 | 6024 | 79697072 |
Excessive eye blinking | 34.21 | 11.71 | 17 | 41275 | 1684 | 79701412 |
Carpal tunnel syndrome | 33.82 | 11.71 | 46 | 41246 | 19482 | 79683614 |
Debridement | 33.80 | 11.71 | 17 | 41275 | 1728 | 79701368 |
Dry skin | 33.56 | 11.71 | 94 | 41198 | 67901 | 79635195 |
Metastases to chest wall | 33.28 | 11.71 | 12 | 41280 | 533 | 79702563 |
Second primary malignancy | 33.10 | 11.71 | 39 | 41253 | 14311 | 79688785 |
Mesenteric vein thrombosis | 33.06 | 11.71 | 17 | 41275 | 1810 | 79701286 |
Intentional product use issue | 32.79 | 11.71 | 19 | 41273 | 152093 | 79551003 |
Oral pain | 32.79 | 11.71 | 59 | 41233 | 31739 | 79671357 |
Pericarditis | 32.70 | 11.71 | 7 | 41285 | 104229 | 79598867 |
Rheumatoid arthritis | 32.48 | 11.71 | 36 | 41256 | 208434 | 79494662 |
Vitreous detachment | 32.38 | 11.71 | 18 | 41274 | 2241 | 79700855 |
Full blood count decreased | 31.89 | 11.71 | 53 | 41239 | 26766 | 79676330 |
Hair growth abnormal | 31.44 | 11.71 | 19 | 41273 | 2765 | 79700331 |
Nail infection | 31.37 | 11.71 | 18 | 41274 | 2381 | 79700715 |
Hyperparathyroidism primary | 31.33 | 11.71 | 11 | 41281 | 452 | 79702644 |
Drug hypersensitivity | 30.94 | 11.71 | 68 | 41224 | 298848 | 79404248 |
Osteoporosis | 30.94 | 11.71 | 79 | 41213 | 54033 | 79649063 |
Dental care | 30.49 | 11.71 | 13 | 41279 | 905 | 79702191 |
Joint neoplasm | 29.88 | 11.71 | 7 | 41285 | 63 | 79703033 |
Nail avulsion | 29.88 | 11.71 | 8 | 41284 | 129 | 79702967 |
Hair texture abnormal | 29.66 | 11.71 | 20 | 41272 | 3514 | 79699582 |
Acute phase reaction | 29.59 | 11.71 | 10 | 41282 | 366 | 79702730 |
Progesterone receptor assay positive | 29.38 | 11.71 | 9 | 41283 | 239 | 79702857 |
Human epidermal growth factor receptor negative | 29.37 | 11.71 | 5 | 41287 | 5 | 79703091 |
Joint stiffness | 29.17 | 11.71 | 65 | 41227 | 40765 | 79662331 |
Cardio-respiratory arrest | 28.95 | 11.71 | 10 | 41282 | 108500 | 79594596 |
Osteomyelitis | 28.94 | 11.71 | 57 | 41235 | 32808 | 79670288 |
PIK3CA-activated mutation | 28.49 | 11.71 | 11 | 41281 | 592 | 79702504 |
Overdose | 28.48 | 11.71 | 32 | 41260 | 184174 | 79518922 |
Leiomyosarcoma recurrent | 28.06 | 11.71 | 5 | 41287 | 8 | 79703088 |
Soft tissue neoplasm | 27.98 | 11.71 | 7 | 41285 | 85 | 79703011 |
Off label use | 27.97 | 11.71 | 318 | 40974 | 906897 | 78796199 |
Sequestrectomy | 27.95 | 11.71 | 12 | 41280 | 850 | 79702246 |
Breast cancer female | 27.86 | 11.71 | 32 | 41260 | 11429 | 79691667 |
Catheter site bruise | 27.66 | 11.71 | 10 | 41282 | 448 | 79702648 |
Metastatic neoplasm | 27.51 | 11.71 | 22 | 41270 | 5020 | 79698076 |
Resorption bone increased | 27.49 | 11.71 | 14 | 41278 | 1461 | 79701635 |
Joint swelling | 27.21 | 11.71 | 69 | 41223 | 288577 | 79414519 |
Pyrexia | 27.21 | 11.71 | 223 | 41069 | 678486 | 79024610 |
Atypical femur fracture | 26.95 | 11.71 | 22 | 41270 | 5167 | 79697929 |
Tendonitis | 26.88 | 11.71 | 46 | 41246 | 23784 | 79679312 |
Bone sequestrum | 26.86 | 11.71 | 13 | 41279 | 1216 | 79701880 |
Pathological fracture | 26.60 | 11.71 | 30 | 41262 | 10507 | 79692589 |
Portal hypertension | 26.58 | 11.71 | 25 | 41267 | 7083 | 79696013 |
Full blood count abnormal | 26.23 | 11.71 | 62 | 41230 | 40412 | 79662684 |
Secondary hypogonadism | 25.86 | 11.71 | 9 | 41283 | 360 | 79702736 |
Septic shock | 25.54 | 11.71 | 16 | 41276 | 122785 | 79580311 |
Tumour marker decreased | 25.51 | 11.71 | 6 | 41286 | 55 | 79703041 |
Metastases to skin | 25.32 | 11.71 | 14 | 41278 | 1725 | 79701371 |
Red blood cell count decreased | 25.01 | 11.71 | 76 | 41216 | 57437 | 79645659 |
Radiation skin injury | 24.96 | 11.71 | 13 | 41279 | 1421 | 79701675 |
Metastases to soft tissue | 24.88 | 11.71 | 10 | 41282 | 599 | 79702497 |
Metastases to the mediastinum | 24.87 | 11.71 | 10 | 41282 | 600 | 79702496 |
Pancreatic neoplasm | 24.61 | 11.71 | 13 | 41279 | 1463 | 79701633 |
Periodontal disease | 24.37 | 11.71 | 14 | 41278 | 1856 | 79701240 |
Sepsis | 24.18 | 11.71 | 66 | 41226 | 269362 | 79433734 |
Diarrhoea | 24.10 | 11.71 | 611 | 40681 | 879878 | 78823218 |
Growth retardation | 23.87 | 11.71 | 14 | 41278 | 1929 | 79701167 |
Glucose tolerance decreased | 23.75 | 11.71 | 6 | 41286 | 76 | 79703020 |
Tooth disorder | 23.71 | 11.71 | 46 | 41246 | 26187 | 79676909 |
Papilloedema | 23.46 | 11.71 | 22 | 41270 | 6211 | 79696885 |
Ascites | 23.30 | 11.71 | 89 | 41203 | 75473 | 79627623 |
Fibrous histiocytoma | 23.28 | 11.71 | 10 | 41282 | 709 | 79702387 |
Back pain | 23.11 | 11.71 | 250 | 41042 | 303930 | 79399166 |
Intraductal proliferative breast lesion | 23.10 | 11.71 | 15 | 41277 | 2476 | 79700620 |
Retinal detachment | 22.78 | 11.71 | 26 | 41266 | 9221 | 79693875 |
Haemorrhoids | 22.66 | 11.71 | 48 | 41244 | 29080 | 79674016 |
Organising pneumonia | 22.42 | 11.71 | 28 | 41264 | 10911 | 79692185 |
Acute kidney injury | 22.02 | 11.71 | 168 | 41124 | 519236 | 79183860 |
Oestradiol abnormal | 21.87 | 11.71 | 5 | 41287 | 40 | 79703056 |
Meningioma | 21.86 | 11.71 | 18 | 41274 | 4280 | 79698816 |
Recall phenomenon | 21.79 | 11.71 | 11 | 41281 | 1126 | 79701970 |
Interstitial lung disease | 21.46 | 11.71 | 115 | 41177 | 112485 | 79590611 |
Asthenia | 21.43 | 11.71 | 378 | 40914 | 511311 | 79191785 |
Metastases to retroperitoneum | 21.36 | 11.71 | 8 | 41284 | 396 | 79702700 |
Febrile neutropenia | 21.16 | 11.71 | 56 | 41236 | 230943 | 79472153 |
Psoriatic arthropathy | 21.13 | 11.71 | 7 | 41285 | 77992 | 79625104 |
Uterine leiomyoma | 20.97 | 11.71 | 21 | 41271 | 6422 | 79696674 |
Ischaemic stroke | 20.65 | 11.71 | 50 | 41242 | 33081 | 79670015 |
Palmar-plantar erythrodysaesthesia syndrome | 20.65 | 11.71 | 50 | 41242 | 33084 | 79670012 |
Cardiac arrest | 20.52 | 11.71 | 36 | 41256 | 172060 | 79531036 |
Bone debridement | 20.44 | 11.71 | 8 | 41284 | 447 | 79702649 |
Carbohydrate antigen 27.29 increased | 20.44 | 11.71 | 5 | 41287 | 55 | 79703041 |
Polymyositis | 20.41 | 11.71 | 15 | 41277 | 3021 | 79700075 |
Stomatitis | 20.37 | 11.71 | 138 | 41154 | 146619 | 79556477 |
Confusional state | 20.36 | 11.71 | 90 | 41202 | 317907 | 79385189 |
Breast mass | 20.14 | 11.71 | 21 | 41271 | 6733 | 79696363 |
Product substitution issue | 20.14 | 11.71 | 37 | 41255 | 20219 | 79682877 |
Invasive lobular breast carcinoma | 20.14 | 11.71 | 9 | 41283 | 702 | 79702394 |
Neoplasm recurrence | 20.09 | 11.71 | 17 | 41275 | 4197 | 79698899 |
General physical health deterioration | 20.08 | 11.71 | 74 | 41218 | 275164 | 79427932 |
Cutaneous vasculitis | 19.99 | 11.71 | 23 | 41269 | 8229 | 79694867 |
Ovarian mass | 19.99 | 11.71 | 8 | 41284 | 474 | 79702622 |
Tumour marker abnormal | 19.95 | 11.71 | 7 | 41285 | 287 | 79702809 |
Dysgeusia | 19.86 | 11.71 | 70 | 41222 | 57107 | 79645989 |
Hyperkalaemia | 19.82 | 11.71 | 18 | 41274 | 114380 | 79588716 |
Superinfection | 19.80 | 11.71 | 18 | 41274 | 4884 | 79698212 |
Carcinoembryonic antigen increased | 19.74 | 11.71 | 13 | 41279 | 2196 | 79700900 |
Transient acantholytic dermatosis | 19.71 | 11.71 | 6 | 41286 | 156 | 79702940 |
Recurrent cancer | 19.69 | 11.71 | 14 | 41278 | 2679 | 79700417 |
Breast haemorrhage | 19.56 | 11.71 | 6 | 41286 | 160 | 79702936 |
Antisynthetase syndrome | 19.35 | 11.71 | 6 | 41286 | 166 | 79702930 |
Madarosis | 19.19 | 11.71 | 14 | 41278 | 2788 | 79700308 |
Metastases to uterus | 19.13 | 11.71 | 5 | 41287 | 73 | 79703023 |
Actinomycosis | 19.06 | 11.71 | 10 | 41282 | 1109 | 79701987 |
Folliculitis | 18.91 | 11.71 | 3 | 41289 | 55377 | 79647719 |
Metastases to bone marrow | 18.89 | 11.71 | 9 | 41283 | 813 | 79702283 |
Jaw operation | 18.82 | 11.71 | 9 | 41283 | 820 | 79702276 |
Gingival swelling | 18.77 | 11.71 | 17 | 41275 | 4592 | 79698504 |
Pleural effusion | 18.64 | 11.71 | 134 | 41158 | 145128 | 79557968 |
Chronic inflammatory demyelinating polyradiculoneuropathy | 18.53 | 11.71 | 10 | 41282 | 1175 | 79701921 |
Performance enhancing product use | 18.48 | 11.71 | 5 | 41287 | 84 | 79703012 |
Gastrointestinal haemorrhage | 18.44 | 11.71 | 30 | 41262 | 147689 | 79555407 |
Blood oestrogen increased | 18.37 | 11.71 | 5 | 41287 | 86 | 79703010 |
Blood pressure fluctuation | 18.24 | 11.71 | 6 | 41286 | 67139 | 79635957 |
Sinusitis | 18.21 | 11.71 | 47 | 41245 | 195454 | 79507642 |
Hypersensitivity | 18.16 | 11.71 | 72 | 41220 | 262167 | 79440929 |
Rhabdomyolysis | 18.14 | 11.71 | 16 | 41276 | 103115 | 79599981 |
Mood swings | 18.13 | 11.71 | 35 | 41257 | 19845 | 79683251 |
Hepatic lesion | 17.88 | 11.71 | 20 | 41272 | 6939 | 79696157 |
Oroantral fistula | 17.83 | 11.71 | 7 | 41285 | 394 | 79702702 |
Mucosal inflammation | 17.81 | 11.71 | 82 | 41210 | 75498 | 79627598 |
Vertebral column mass | 17.71 | 11.71 | 6 | 41286 | 221 | 79702875 |
Pain in extremity | 17.71 | 11.71 | 276 | 41016 | 364262 | 79338834 |
Spondylolisthesis | 17.63 | 11.71 | 14 | 41278 | 3161 | 79699935 |
Neuroectodermal neoplasm | 17.62 | 11.71 | 3 | 41289 | 3 | 79703093 |
Metastases to peritoneum | 17.56 | 11.71 | 16 | 41276 | 4356 | 79698740 |
Autoimmune pancreatitis | 17.45 | 11.71 | 8 | 41284 | 662 | 79702434 |
Gene mutation | 17.45 | 11.71 | 13 | 41279 | 2673 | 79700423 |
Decreased appetite | 17.31 | 11.71 | 261 | 41031 | 342157 | 79360939 |
Unresponsive to stimuli | 16.99 | 11.71 | 4 | 41288 | 55784 | 79647312 |
Borrelia infection | 16.99 | 11.71 | 6 | 41286 | 251 | 79702845 |
Osteosclerosis | 16.87 | 11.71 | 15 | 41277 | 3956 | 79699140 |
Metabolic acidosis | 16.82 | 11.71 | 11 | 41281 | 82518 | 79620578 |
Hypoaesthesia teeth | 16.61 | 11.71 | 4 | 41288 | 41 | 79703055 |
Cholestasis | 16.58 | 11.71 | 62 | 41230 | 52047 | 79651049 |
Hydrothorax | 16.53 | 11.71 | 10 | 41282 | 1458 | 79701638 |
Spinal pain | 16.43 | 11.71 | 29 | 41263 | 15363 | 79687733 |
Vitreous adhesions | 16.27 | 11.71 | 4 | 41288 | 45 | 79703051 |
Abdominal wall cyst | 16.27 | 11.71 | 4 | 41288 | 45 | 79703051 |
Oestradiol decreased | 16.09 | 11.71 | 3 | 41289 | 7 | 79703089 |
Hair colour changes | 16.05 | 11.71 | 15 | 41277 | 4217 | 79698879 |
Mastectomy | 16.02 | 11.71 | 9 | 41283 | 1143 | 79701953 |
Pustule | 15.91 | 11.71 | 11 | 41281 | 2014 | 79701082 |
Poor peripheral circulation | 15.82 | 11.71 | 14 | 41278 | 3669 | 79699427 |
Muscle injury | 15.77 | 11.71 | 3 | 41289 | 48558 | 79654538 |
Respiratory failure | 15.71 | 11.71 | 45 | 41247 | 180866 | 79522230 |
Exposed bone in jaw | 15.70 | 11.71 | 14 | 41278 | 3706 | 79699390 |
C-reactive protein abnormal | 15.68 | 11.71 | 3 | 41289 | 48364 | 79654732 |
Toothache | 15.64 | 11.71 | 33 | 41259 | 19937 | 79683159 |
Drug intolerance | 15.57 | 11.71 | 77 | 41215 | 264042 | 79439054 |
Rhabdomyosarcoma | 15.46 | 11.71 | 5 | 41287 | 159 | 79702937 |
Portal vein thrombosis | 15.41 | 11.71 | 17 | 41275 | 5810 | 79697286 |
Benign lymph node neoplasm | 15.31 | 11.71 | 3 | 41289 | 10 | 79703086 |
Henoch-Schonlein purpura | 15.16 | 11.71 | 12 | 41280 | 2698 | 79700398 |
Retinopathy | 15.16 | 11.71 | 14 | 41278 | 3877 | 79699219 |
Ovarian cancer | 15.03 | 11.71 | 14 | 41278 | 3920 | 79699176 |
Pneumonia aspiration | 14.95 | 11.71 | 8 | 41284 | 66959 | 79636137 |
Breast cancer in situ | 14.84 | 11.71 | 8 | 41284 | 938 | 79702158 |
Polycythaemia | 14.72 | 11.71 | 11 | 41281 | 2273 | 79700823 |
Granulocyte count decreased | 14.62 | 11.71 | 10 | 41282 | 1798 | 79701298 |
Breast swelling | 14.52 | 11.71 | 9 | 41283 | 1371 | 79701725 |
C-reactive protein increased | 14.48 | 11.71 | 28 | 41264 | 128999 | 79574097 |
Disease recurrence | 14.47 | 11.71 | 53 | 41239 | 44056 | 79659040 |
Lichen sclerosus | 14.46 | 11.71 | 8 | 41284 | 986 | 79702110 |
Neuralgia | 14.40 | 11.71 | 44 | 41248 | 33340 | 79669756 |
Urinary casts present | 14.37 | 11.71 | 4 | 41288 | 75 | 79703021 |
Squamous cell breast carcinoma | 14.33 | 11.71 | 3 | 41289 | 15 | 79703081 |
Tooth loss | 14.32 | 11.71 | 18 | 41274 | 7057 | 79696039 |
Tremor | 14.27 | 11.71 | 43 | 41249 | 170040 | 79533056 |
Hypercalcaemia | 14.17 | 11.71 | 48 | 41244 | 38382 | 79664714 |
Chronic hepatitis | 14.12 | 11.71 | 9 | 41283 | 1438 | 79701658 |
Blood testosterone increased | 14.04 | 11.71 | 8 | 41284 | 1044 | 79702052 |
Urticaria | 14.02 | 11.71 | 49 | 41243 | 185152 | 79517944 |
Meibomian gland dysfunction | 14.00 | 11.71 | 5 | 41287 | 216 | 79702880 |
Coma | 13.96 | 11.71 | 19 | 41273 | 100630 | 79602466 |
Sjogren's syndrome | 13.87 | 11.71 | 7 | 41285 | 717 | 79702379 |
Vascular purpura | 13.75 | 11.71 | 12 | 41280 | 3086 | 79700010 |
Postoperative wound complication | 13.75 | 11.71 | 9 | 41283 | 1505 | 79701591 |
Bone marrow infiltration | 13.67 | 11.71 | 7 | 41285 | 739 | 79702357 |
Product use in unapproved indication | 13.63 | 11.71 | 75 | 41217 | 250284 | 79452812 |
Autoimmune hepatitis | 13.63 | 11.71 | 23 | 41269 | 11760 | 79691336 |
Electrocardiogram QT interval | 13.62 | 11.71 | 5 | 41287 | 234 | 79702862 |
Loss of personal independence in daily activities | 13.60 | 11.71 | 20 | 41272 | 102560 | 79600536 |
Intermenstrual bleeding | 13.59 | 11.71 | 16 | 41276 | 5868 | 79697228 |
Multiple organ dysfunction syndrome | 13.57 | 11.71 | 26 | 41266 | 120220 | 79582876 |
Dental caries | 13.57 | 11.71 | 23 | 41269 | 11797 | 79691299 |
Tachycardia | 13.48 | 11.71 | 47 | 41245 | 177721 | 79525375 |
Sedation | 13.47 | 11.71 | 5 | 41287 | 51890 | 79651206 |
White blood cell disorder | 13.44 | 11.71 | 12 | 41280 | 3180 | 79699916 |
Cutaneous sarcoidosis | 13.44 | 11.71 | 6 | 41286 | 467 | 79702629 |
Uveitis | 13.40 | 11.71 | 28 | 41264 | 16802 | 79686294 |
Lower limb fracture | 13.38 | 11.71 | 34 | 41258 | 23181 | 79679915 |
BRCA2 gene mutation | 13.36 | 11.71 | 4 | 41288 | 98 | 79702998 |
Varicophlebitis | 13.35 | 11.71 | 3 | 41289 | 22 | 79703074 |
Dark circles under eyes | 13.27 | 11.71 | 6 | 41286 | 481 | 79702615 |
Suicide attempt | 13.26 | 11.71 | 14 | 41278 | 82918 | 79620178 |
Drug ineffective for unapproved indication | 13.19 | 11.71 | 5 | 41287 | 51233 | 79651863 |
Cytomegalovirus infection | 13.10 | 11.71 | 3 | 41289 | 42641 | 79660455 |
Metastases to eye | 13.08 | 11.71 | 5 | 41287 | 262 | 79702834 |
Cardiotoxicity | 12.99 | 11.71 | 23 | 41269 | 12216 | 79690880 |
Pelvic mass | 12.95 | 11.71 | 8 | 41284 | 1211 | 79701885 |
Injection site pruritus | 12.94 | 11.71 | 3 | 41289 | 42280 | 79660816 |
Left ventricular dysfunction | 12.91 | 11.71 | 30 | 41262 | 19331 | 79683765 |
Medication error | 12.87 | 11.71 | 10 | 41282 | 68632 | 79634464 |
Visual acuity reduced | 12.86 | 11.71 | 39 | 41253 | 29430 | 79673666 |
Blood alkaline phosphatase increased | 12.80 | 11.71 | 66 | 41226 | 63598 | 79639498 |
Injection site erythema | 12.73 | 11.71 | 13 | 41279 | 78184 | 79624912 |
Agitation | 12.68 | 11.71 | 20 | 41272 | 99695 | 79603401 |
Bacteriuria | 12.64 | 11.71 | 8 | 41284 | 1263 | 79701833 |
Plantar fasciitis | 12.61 | 11.71 | 12 | 41280 | 3448 | 79699648 |
Rouleaux formation | 12.61 | 11.71 | 3 | 41289 | 29 | 79703067 |
Blood copper increased | 12.61 | 11.71 | 3 | 41289 | 29 | 79703067 |
Adenomyosis | 12.51 | 11.71 | 5 | 41287 | 295 | 79702801 |
Wheezing | 12.50 | 11.71 | 26 | 41266 | 116638 | 79586458 |
Paraesthesia | 12.50 | 11.71 | 143 | 41149 | 176180 | 79526916 |
Bronchitis | 12.47 | 11.71 | 31 | 41261 | 130613 | 79572483 |
Wound | 12.36 | 11.71 | 26 | 41266 | 116153 | 79586943 |
Renal vein thrombosis | 12.36 | 11.71 | 6 | 41286 | 565 | 79702531 |
Wrong technique in product usage process | 12.35 | 11.71 | 12 | 41280 | 73863 | 79629233 |
Subacute cutaneous lupus erythematosus | 12.32 | 11.71 | 12 | 41280 | 3549 | 79699547 |
Visual field defect | 12.29 | 11.71 | 19 | 41273 | 9026 | 79694070 |
Alopecia areata | 12.15 | 11.71 | 9 | 41283 | 1834 | 79701262 |
Vertigo | 12.12 | 11.71 | 69 | 41223 | 69013 | 79634083 |
Dyshidrotic eczema | 12.05 | 11.71 | 6 | 41286 | 597 | 79702499 |
Heart rate increased | 12.04 | 11.71 | 28 | 41264 | 120696 | 79582400 |
Dysaesthesia | 12.03 | 11.71 | 15 | 41277 | 5833 | 79697263 |
Oxygen saturation decreased | 12.03 | 11.71 | 31 | 41261 | 129016 | 79574080 |
Mucosal ulceration | 12.02 | 11.71 | 9 | 41283 | 1864 | 79701232 |
Arthropathy | 12.02 | 11.71 | 49 | 41243 | 177062 | 79526034 |
Uterine cancer | 11.96 | 11.71 | 12 | 41280 | 3679 | 79699417 |
Peripheral sensory neuropathy | 11.95 | 11.71 | 23 | 41269 | 13010 | 79690086 |
Meniscus injury | 11.80 | 11.71 | 16 | 41276 | 6752 | 79696344 |
Dupuytren's contracture | 11.80 | 11.71 | 3 | 41289 | 39 | 79703057 |
Irritable bowel syndrome | 11.76 | 11.71 | 9 | 41283 | 62232 | 79640864 |
None
Source | Code | Description |
---|---|---|
ATC | L02BG03 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ENDOCRINE THERAPY HORMONE ANTAGONISTS AND RELATED AGENTS Aromatase inhibitors |
FDA MoA | N0000175080 | Aromatase Inhibitors |
FDA EPC | N0000175563 | Aromatase Inhibitor |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:50790 | aromatase inhibitors |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D018931 | Antineoplastic Agents, Hormonal |
MeSH PA | D047072 | Aromatase Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D004965 | Estrogen Antagonists |
MeSH PA | D006727 | Hormone Antagonists |
MeSH PA | D065088 | Steroid Synthesis Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hormone receptor positive malignant neoplasm of breast | indication | 417181009 | |
Malignant tumor of ovary | off-label use | 363443007 | DOID:2394 |
Hypercholesterolemia | contraindication | 13644009 | |
Pregnancy, function | contraindication | 289908002 | |
Osteopenia | contraindication | 312894000 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 3.56 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Aromatase | Enzyme | INHIBITOR | IC50 | 6.22 | WOMBAT-PK | CHEMBL |
ID | Source |
---|---|
4020948 | VUID |
N0000148427 | NUI |
D00960 | KEGG_DRUG |
262485 | RXNORM |
C0290883 | UMLSCUI |
CHEBI:2704 | CHEBI |
CHEMBL1399 | ChEMBL_ID |
DB01217 | DRUGBANK_ID |
D000077384 | MESH_DESCRIPTOR_UI |
2187 | PUBCHEM_CID |
5137 | IUPHAR_LIGAND_ID |
7274 | INN_ID |
2Z07MYW1AZ | UNII |
173198 | MMSL |
4200 | MMSL |
5599 | MMSL |
d03873 | MMSL |
108774000 | SNOMEDCT_US |
386910003 | SNOMEDCT_US |
4020948 | VANDF |
005094 | NDDF |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Anastrozole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7536 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 28 sections |
Anastrozole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7536 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 28 sections |
ARIMIDEX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0310-0201 | TABLET | 1 mg | ORAL | NDA | 28 sections |
Anastrozole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-5356 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 29 sections |
Anastrozole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6195 | TABLET | 1 mg | ORAL | ANDA | 26 sections |
Anastrozole | Human Prescription Drug Label | 1 | 16571-421 | TABLET | 1 mg | ORAL | ANDA | 29 sections |
Anastrozole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-035 | TABLET | 1 mg | ORAL | ANDA | 26 sections |
Anastrozole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-990 | TABLET | 1 mg | ORAL | ANDA | 27 sections |
Anastrozole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-857 | TABLET | 1 mg | ORAL | ANDA | 28 sections |
Anastrozole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-161 | TABLET | 1 mg | ORAL | ANDA | 28 sections |
ANASTROZOLE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-016 | TABLET | 1 mg | ORAL | ANDA | 32 sections |
Anastrozole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-085 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 28 sections |
Anastrozole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-085 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 28 sections |
ANASTROZOLE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-383 | TABLET | 1 mg | ORAL | ANDA | 33 sections |
ANASTROZOLE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-383 | TABLET | 1 mg | ORAL | ANDA | 33 sections |
ANASTROZOLE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-383 | TABLET | 1 mg | ORAL | ANDA | 33 sections |
Anastrozole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45865-909 | TABLET | 1 mg | ORAL | ANDA | 27 sections |
Anastrozole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-2453 | TABLET | 1 mg | ORAL | ANDA | 28 sections |
Anastrozole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-2453 | TABLET | 1 mg | ORAL | ANDA | 28 sections |
Anastrozole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-2453 | TABLET | 1 mg | ORAL | ANDA | 28 sections |
ANASTROZOLE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5002 | TABLET | 1 mg | ORAL | ANDA | 30 sections |
Anastrozole | Human Prescription Drug Label | 1 | 50090-5812 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 28 sections |
Anastrozole | Human Prescription Drug Label | 1 | 50090-5812 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 28 sections |
ANASTROZOLE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-075 | TABLET | 1 mg | ORAL | ANDA | 31 sections |
Anastrozole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51655-638 | TABLET | 1 mg | ORAL | ANDA | 15 sections |
ANASTROZOLE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51991-620 | TABLET | 1 mg | ORAL | ANDA | 33 sections |
ANASTROZOLE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51991-620 | TABLET | 1 mg | ORAL | ANDA | 33 sections |
ANASTROZOLE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51991-620 | TABLET | 1 mg | ORAL | ANDA | 33 sections |
ARIMIDEX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5000 | TABLET | 1 mg | ORAL | NDA | 28 sections |
Anastrozole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6130 | TABLET | 1 mg | ORAL | ANDA | 27 sections |